Dexpramipexole

Highly related to the Parkinson’s disease drug pramipexole (Mirapex), the neuroprotectant dexpramipexole (Empower) may slow the progression of ALS by keeping the power on in deteriorating motor nerves. Dexpramipexole is thought to maintain mitochondrial function in people with ALS by increasing the efficiency of ATP production.

Status

Type:	Small Molecule
Stage:	Phase III
Status:	Completed
Sponsor:	Biogen Idec

TDI Says:

A Phase III clinical trial on dexpramipexole was completed in 2012. Results and analysis reported by clinical trial sponsor Biogen Idec showed no statistically significant slowing of disease progression in people with ALS treated with dexpramipexole compared to those treated with placebo.

Learn More

ALS clinical trials, powering forward

Biogen Idec's Doug Kerr MD PhD talks dexpramipexole - the lessons learned and the development of future ALS medicines going forward.
ALS/MND 2012: Trials and tribulations

Emerging ALS medicines show promise. But key challenges remain to bring them forward to the ALS clinic according to new studies unveiled at ALS MND Chicago.
ALS, off the beaten track

Emerging ALS mitochondrial-targeted medicines are gathering steam. But, these medicines may need to do a lot more than boost energy production to stop the disease.

Published Results

Dexpramipexole Is Ineffective in Two Models of ALS Related Neurodegeneration

ALS TDI scientists publish new results from preclinical study of dexpramipexole.
The Combined Assessment of Function and Survival (CAFS): a new endpoint for ALS clinical trials.

Joint rank analysis is introduced in hopes to better estimate efficacy of potential ALS drugs in clinical trials
The effects of dexpramipexole (KNS-760704) in individuals with ALS

300mg dexpramipexole daily slowed progression of ALS 30% according to a placebo-controlled phase II trial of 104 PALS

Comment on this Topic

(All comments are moderated before they appear here.)

Mitochondrial Dysfuntion

Topics in the Pipeline

Dexpramipexole

Status

TDI Says:

Learn More

ALS clinical trials, powering forward

ALS/MND 2012: Trials and tribulations

ALS, off the beaten track

Published Results

Dexpramipexole Is Ineffective in Two Models of ALS Related Neurodegeneration

The Combined Assessment of Function and Survival (CAFS): a new endpoint for ALS clinical trials.

The effects of dexpramipexole (KNS-760704) in individuals with ALS

Comment on this Topic